[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100493616":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":41,"responsibleParty":115,"collaborators":26,"id":119,"slug":26,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":26,"eligibilityCriteria":124,"healthyVolunteers":120,"sex":125,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":26,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":26,"overallStatus":137,"whyStopped":26,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Changhai Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"A (hormone)","ACTIVE_COMPARATOR","The patients in arm A with oligometastatic PCa will receive long-term ADT combined with abiraterone.",[13],"Drug: ADT combined with abiraterone",{"label":15,"type":16,"description":17,"interventionNames":18},"B (neoadjuvant hormone and RT)","EXPERIMENTAL","The patients in arm B with oligometastatic PCa will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.",[19],"Radiation: neoadjuvant hormone and RT",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","ADT combined with abiraterone","The patients will receive long-term ADT combined with abiraterone.",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"RADIATION","neoadjuvant hormone and RT","The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.",[15],[33,38],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Huojun Zhang, PhD","CONTACT","021-31162222","huojunzh@163.com",{"name":39,"role":35,"phone":36,"phoneExt":26,"email":40},"Xianzhi Zhao, MD","zhxzh0007@163.com",[42,57,69,81,93,107],{"facility":43,"status":26,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"the First Affiliated Hospital of Guangzhou Medical University","Guangzhou","Guangdong","510120","China",{"type":49,"coordinates":50},"Point",[51,52],113.25,23.11667,{"lat":52,"lon":51},[55],{"name":56,"role":35,"phone":26,"phoneExt":26,"email":26},"Di Gu, PhD",{"facility":58,"status":26,"city":59,"state":60,"zip":26,"country":47,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"First Affiliated Hospital and Medical College of Soochow University","Suzhou","Jiangsu",{"type":49,"coordinates":62},[63,64],120.59538,31.30408,{"lat":64,"lon":63},[67],{"name":68,"role":35,"phone":26,"phoneExt":26,"email":26},"Xiang Ding, PhD",{"facility":70,"status":26,"city":71,"state":60,"zip":72,"country":47,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Jiangnan University Medical Center","Wuxi","210009",{"type":49,"coordinates":74},[75,76],120.28857,31.56887,{"lat":76,"lon":75},[79],{"name":80,"role":35,"phone":26,"phoneExt":26,"email":26},"Ninghan Feng, PhD",{"facility":82,"status":26,"city":83,"state":84,"zip":26,"country":47,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"The First Affiliated Hospital of Ningbo University","Ningbo","Zhejiang",{"type":49,"coordinates":86},[87,88],121.54945,29.87819,{"lat":88,"lon":87},[91],{"name":92,"role":35,"phone":26,"phoneExt":26,"email":26},"Zejun Yan, PhD",{"facility":94,"status":26,"city":95,"state":26,"zip":96,"country":47,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"The Second Affiliated Hospital of Naval Medical University","Shanghai","200003",{"type":49,"coordinates":98},[99,100],121.45806,31.22222,{"lat":100,"lon":99},[103],{"name":104,"role":35,"phone":105,"phoneExt":26,"email":106},"Shancheng Ren, PhD","021-81885721","renshancheng@gmail.com",{"facility":108,"status":26,"city":95,"state":26,"zip":109,"country":47,"cosmosGeoPoint":110,"geoPoint":112,"contacts":113},"The First Affiliated Hospital of Naval Medical University","200433",{"type":49,"coordinates":111},[99,100],{"lat":100,"lon":99},[114],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},{"type":116,"investigatorFullName":117,"investigatorTitle":118,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Zhang Huo Jun","Director","100493616",false,"NCT05707468","Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer","Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: a Multi-center Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the prostate without small cell features\n* Oligometastatic PCa assessed by Ga-68 prostate-specific membrane antigen (PSMA), PET\u002FCT\n* \\\u003C4 bone oligometastases, lymph node metastasis below the renal artery level\n* Expected survival time \\>5 years\n* World Health Organization (WHO) performance status 0-1\n* Be willing to give written informed consent.\n\nExclusion Criteria:\n\n* Any previous or ongoing treatment for PCa, including radiotherapy, ADT, chemotherapy, focal treatment, etc.\n* Patients who have previously undergone transurethral resection or enucleation of the prostate.\n* Patients who have undergone other abdominal surgery within the last 3 months\n* Patients who have visceral metastases\n* Patients with a history of long-term anticoagulant use and anti-platelet drug use and who stopped anticoagulant therapy less than 1 week before registration\n* Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and\u002For positive syphilis\n* Severe or active comorbidities likely to impact the advisability of radiotherapy\n* Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which, according to the judgement of the investigator, may affect the planned staging, treatment and follow-up or patient compliance or may cause high-risk treatmentrelated complications for the patient\n* Patients who have participated in other clinical trials within the last 3 months\n* Patients who refuse to undergo RALP\n* Patients unsuitable for participation in this clinical trial as per the judgement of the investigator.","MALE","18 Years","75 Years",{"count":129,"type":130},200,"ESTIMATED","INTERVENTIONAL",[133],"NA","The optimal treatment for oligometastatic prostate cancer (OMPC) is still on its way. Accumulating evidence has proven the safety and feasibility of radical prostatectomy and local or metastasis-directed radiotherapy for oligometastatic patients. The aim of this trial is to compare the safety and feasibility outcomes of metastasis-directed neoadjuvant radiotherapy (naRT) and neoadjuvant androgen deprivation therapy (naADT) followed by robotic-assisted radical prostatectomy (RARP) to ADT combined with abiraterone for treating OMPC.",[136],"Oligometastatic Prostate Carcinoma","NOT_YET_RECRUITING","2024-02-19",{"date":140,"type":141},"2024-02-20","ACTUAL",{"date":143,"type":130},"2024-05-01",{"date":145,"type":130},"2028-03-01",{"name":5,"class":6},6]